Posted by Michael Wonder on 03 May 2021
Hutchmed completes rolling submission of NDA to U.S. FDA for surufatinib for the treatment of advanced neuroendocrine tumours
3 May 2021 - First NDA submission by Hutchmed in the U.S.; product launch preparations underway.
Hutchmed today announces that it completed the rolling submission of a new drug application to the U.S. FDA for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumours.
